From the Department of Obstetrics and Gynecology, University of California, Irvine, Irvine, California; Tucson Medical Center, Tucson, Arizona; Forsyth Medical Center, Winston-Salem, North Carolina; Cytokine Pharmasciences, Inc., Kink of Prussia, Pennsylvania; and the Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, New Mexico.
*For a list of the institutions that participated in this study, see the Appendix online at https://links.lww.com/AOG/A219.
Sponsored by Controlled Therapeutics (Scotland) Ltd (East Kilbride, UK), a wholly-owned subsidiary of Cytokine Pharmasciences, Inc. (King of Prussia, PA).
The authors thank the innumerable contributions of Pamela J. Rumney, RNC, CCRC, and Christine W. Preslicka, RN, BSN, CCRC, for protocol development, oversight, and execution.
Presented at the Annual Meeting of the Society for Maternal-Fetal Medicine, February 7–12, 2011, San Francisco, California.
Corresponding author: Deborah A. Wing, MD, Department of Obstetrics and Gynecology, University of California, Irvine, 101 The City Drive South, Building 56, Suite 800, Orange, California 92868; e-mail: [email protected].
Financial Disclosure Dr. Wing was the primary investigator for this multicenter consortium. Dr. Powers is an employee of Cytokine Pharmasciences, Inc., and Drs. Miller, Parker and Rayburn were site principal investigators for Cytokine Pharmasciences, Inc., King of Prussia, Pennsylvania.
